Biograil Raises €20 Million to Push Oral Biologic Delivery Into Clinics

Copenhagen's Biograil raises €20 million from Verve Ventures, Megatrend Invest and HTGF to advance its capsule-based BIONDD® oral delivery platform toward Phase 1 trials.